New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 2, 2012
09:51 EDTVRTX, MTL, IRDM, FLR, EXC, SPR, LPNT, HTGC, FSLR, EPL, RRD, LVS, GES, FIATY, SAM, ABX, AAWWOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Atlas Air (AAWW) downgraded to Equal Weight from Overweight at Stephens... Barrick Gold (ABX) downgraded to Market Perform from Outperform at BMO Capital... Boston Beer (SAM) downgraded to Outperform from Buy at CLSA... Energy Partners (EPL) downgraded to Accumulate from Buy at Global Hunter... Exelon (EXC) downgraded to Hold from Buy at Jefferies... Fiat (FIATY) downgraded to Neutral from Buy at UBS... First Solar (FSLR) downgraded to Hold from Buy at Cantor... Fluor (FLR) downgraded to Neutral from Outperform at RW Baird... Guess (GES) downgraded to Hold from Buy at Jefferies... Hercules Technology (HTGC) downgraded to Neutral from Outperform at RW Baird... Iridium (IRDM) downgraded to Fair Value from Buy at CRT Capital... Las Vegas Sands (LVS) downgraded to Hold from Buy at Cantor... LifePoint Hospitals (LPNT) downgraded to Hold from Buy at Cantor... Mechel (MTL) downgraded to Neutral from Overweight at JPMorgan... R.R. Donnelley (RRD) downgraded to Neutral from Buy at CL King... Spirit AeroSystems (SPR) downgraded to Neutral from Outperform at Cowen... Vertex (VRTX) downgraded to Sell from Neutral at Goldman.
News For AAWW;ABX;SAM;EPL;EXC;FIATY;FSLR;FLR;GES;HTGC;IRDM;LVS;LPNT;MTL;RRD;SPR;VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 21, 2015
10:30 EDTVRTXVertex management to meet with Maxim
Subscribe for More Information
May 20, 2015
08:44 EDTFLRFluor shares attractive amid transition to nat gas, says Sterne Agee CRT
Subscribe for More Information
May 19, 2015
15:36 EDTEXCPepco takeover by Exelon approved by Delaware regulators, Bloomberg reports
Delaware's PSC voted 3-0 in favor of approving he takeover, Bloomberg reported, citing an email statement from a spokesman for the regulator.
08:10 EDTEXCHouse Energy & Commerce Committee to hold a hearing
The Energy & Power Subcommittee holds a hearing entitled, "Discussion Draft Addressing Energy Reliability and Security" with Director Bardee of FERC, President & CEO Fanning of Southern Company, Executive Vice President Dominguez of Exelon Corp., and Vice President Heitman of ABB, Inc. on May 19 at 10 am. Webcast Link
07:56 EDTVRTXGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
May 18, 2015
10:01 EDTLVSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:02 EDTEXCExelon, Pepco accept, pledge to fulfill conditions in merger order from MPSC
Subscribe for More Information
07:40 EDTLVSLas Vegas Sands downgraded to Neutral from Buy at Goldman
Subscribe for More Information
May 17, 2015
13:46 EDTVRTXVertex reports Orkambi data, says 'significant improvements' in primary endpoint
Vertex Pharmaceuticals announced that the New England Journal of Medicine published data from the two phase 3 studies of Orkambi, or lumacaftor/ivacaftor, a medicine designed to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. In November 2014, Vertex submitted an NDA to the FDA for the combination of lumacaftor and ivacaftor. On May 12th, the FDA’s Pulmonary Allergy Drugs Advisory Committee voted 12-1 to recommend approval of Orkambi for people ages 12 and older with two copies of the F508del mutation. The FDA is expected to make a decision by July 5. The New England Journal reports that the studies enrolled 1108 patients who underwent randomization and received Orkambi. In both studies, there were significant improvements in the primary end point in both lumacaftor–ivacaftor dose groups. The difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV ranged 2.6%-4%, which corresponded to a mean relative treatment difference of 4.3 to 6.7%. Pooled analyses showed that the rate of pulmonary exacerbations was 30%-39% lower than in the placebo group. The rate of events leading to hospitalization or the use of intravenous antibiotics was also lower. The incidence of adverse events was generally similar to the placebo group.
May 15, 2015
14:46 EDTEXCExelon, Pepco say MPSC approval must be 'carefully' reviewed
Subscribe for More Information
13:38 EDTEXCMaryland PSC conditionally approves Exelon, Pepco merger
Subscribe for More Information
10:29 EDTLPNTAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTVRTXAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
05:43 EDTLVSWynn Resorts downgraded to Equal Weight from Overweight at Barclays
Subscribe for More Information
May 14, 2015
13:02 EDTLPNTLifePoint and Watertown Regional Medical Center agrees to partnership
Subscribe for More Information
08:02 EDTLPNTHealthcare Facilities sector upgraded to Attractive at Morgan Stanley
Subscribe for More Information
May 13, 2015
16:19 EDTSAMBoston Beer expands repurchase program by $50M
At a special meeting of the board of directors of The Boston Beer Company held on May 8, the board voted to increase the aggregate expenditure limit for the company's stock repurchase program by $50M, thereby increasing the limit from $350M to $400M. Shares of the company's class A common stock will be repurchased pursuant to a rule 10b5-1 plan. As of May 8, the company had approximately $28.3M remaining on the $350M repurchase limit.
09:35 EDTLVSLas Vegas Sands' Q1 revenues tracking slightly below Street, says ITG Research
ITG Research said Las Vegas Sands' Q1 net revenues are tracking in the range of $2.95B-$3B, below consensus of $3.03B.
07:25 EDTFLRUBS to hold a tour
Subscribe for More Information
07:19 EDTVRTXVertex shares should have upward momentum in near-term, says JMP Securities
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use